Merck combo helps hep C patients in HIV population; GSK and J&J to test once-monthly AIDS therapy;

@FierceBiotech: Read about the reasons that put these 15 cities at the top of U.S. Report | Follow @FierceBiotech

@JohnCFierce: Forest's CNS partner Adamas shoots for #IPO gold in $69M offering. Story | Follow @JohnCFierce

@DamianFierce: Endo wins FDA nod for a "low-T" drug just as safety controversy reaches fever pitch. News | Follow @DamianFierce

@EmilyMFierce: Super cool: A new kind of wristband could measure individual exposure to environmental toxins. More | Follow @EmilyMFierce

> A pair of Merck ($MRK) drugs--MK-5172 and MK-8742--proved very effective in treating hepatitis C patients who were also infected with HIV. Story

> GlaxoSmithKline ($GSK) and Johnson & Johnson ($JNJ) are partnering on a study of a new, once-monthly AIDS drug. The combination of Glaxo's GSK1265744 and J&J's Edurant beat Sustiva in a head-to-head study. Report

> Ampio Pharmaceuticals ($AMPE) has raised $63.3 million from a stock offering. Story

> Hawaii Biotech has landed a $5.5 million DoD contract to further develop its anti-botulism drugs. Story

Medical Device News

@FierceMedDev: The vaginal mesh saga continues: Coloplast reportedly paid $16M to settle suits, sparking talk of a global settlement. More | Follow @FierceMedDev

@MarkHFierce: Navidea is trying to move its Lymphoseek cancer imaging agent forward in the mkt, and this $30M loan will help. Story | Follow @MarkHFierce

@GalenMoore: Upheld: Former Spectranetics CEO's conviction for lying to the feds over device smuggling allegations. Story | Follow @GalenMoore

@EmilyWFierce: Pulse Therapeutics' magnet-based technology could help deliver drugs to stroke patients faster, improving outcomes. News | Follow @EmilyWFierce

> Researchers find silk could replace metal in surgical devices. More

> Study gives KCI's wound therapy device a marketplace boost. Article

Pharma News

@FiercePharma: Study: Pro-vaccine messages can intensify immunization opposition - FierceVaccines. More | Follow @FiercePharma

@TracyStaton: Which city boasts the most biotech VC funding? Check out the top 15 list at FierceBiotech. Report | Follow @TracyStaton

@EricPFierce: Baxter says it discovered mold in a dialysis product. FDA sent it a warning letter last year related to mold. Story | Follow @EricPFierce

@CarlyHFierce: "The constant threat of compulsory licences hangs like a Damocles sword over patent-holders." Article | Follow @CarlyHFierce

> Endo finally wins a Low-T drug nod, but safety dispute could snarl its launch. Story

> Italian prosecutors jump into Roche, Novartis case with fraud probe. News

> Merck shores up Rebif defenses to fend off new MS rivals. More

Pharma Manufacturing News

> Baxter recalls a dialysis product due to mold. News

> Plant issues cost Lilly, Boehringer Ingelheim a drug approval. Story

> Lilly and its partner Novast start work on a plant in China. Story

> Sagent recalls drug because of leaking bags. News

> Bloomberg: Worker safety also an issue with Ranbaxy plant. Article

> GSK shares grant to help U.K. on how to rebuild its drug manufacturing base. Brief

Vaccines News

> U.K. facing $100M compensation payout relating to GSK's swine flu vaccine. Report

> Study: Merck's Gardasil halves risk of precancerous lesions. Story

> Sanofi makes inactive polio vax available to poor countries for a buck a dose. Article

> CDC reports switch to 2-dose regimen of Merck's chickenpox vaccine a success. Story

> Pro-vaccine messages can intensify immunization opposition. Study

> Antibody discovery opens new avenue for HIV vaccine development. Brief

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.